Eevia Health Oyj, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant material from the pristine Finnish forests near the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. The focus is on ingredients that protect human health prophylactically, meaning they work to reduce the risk of deteriorating health or even developing a disease. In its portfolio, Eevia Health has immune-modulating products that have effects on Th1-type cytokines, such as IFN- and TNF-α cell signaling molecules, which are very important in the immune response to pathogens (virus, bacteria). Similarly, Eevia Health is developing a new product that prevents protein accumulation in the RPE-cells in the Retina, which may reduce the risk of developing eye disease AMD (Age-Related Macular Degeneration).

Eevia Health is a small, but fast-growing Finnish manufacturer of 100% organically certified plant extracts. Most of its raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion. The safe and effective ingredients of high quality, such as high concentrate bilberry anthocyanin extracts (36%) and pine bark extracts (70% oligomeric proanthocyanidins), are organically certified. Eevia Health operates a modern green-chemistry production facility in Finland, located close to the raw materials. The short value-chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.